Le Lézard

Communiqués de presse par sujet : Essais cliniques / Découvertes médicales

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

27 novembre 2017

05:00
Researchers using functional MRI (fMRI) have found that neurofeedback training has the potential to reduce the severity of tinnitus or even eliminate it, according to a study presented today at the annual meeting of the Radiological Society of North...

04:00
TauRx Therapeutics Ltd today reported the full results from its second Phase 3 clinical study of LMTX®, the first tau aggregation inhibitor in Alzheimer's disease, published online in the Journal of Alzheimer's Disease.       (Logo:...

03:00
TauRx Therapeutics Ltd a annoncé aujourd'hui les résultats complets de sa deuxième étude clinique de phase 3 portant sur LMTX®, le premier inhibiteur de l'agrégation de la protéine tau dans le cadre de la maladie d'Alzheimer. Ces résultats ont été...

03:00
Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") announced today completion of enrollment in Study BHV3000-302, the Company's second pivotal Phase 3 clinical trial examining the efficacy and safety of rimegepant in the...

02:00
Regeneron Pharmaceuticals, Inc.  today announced that results from two Phase 2 studies that added the angiopoietin2 (Ang2) antibody nesvacumab to EYLEA® (aflibercept) Injection did not provide sufficient differentiation to warrant Phase 3...

01:00
Submission based on positive results from two clinical trials  Pharming Group N.V. ("Pharming" or "the Company") (Euronext Amsterdam: PHARM) announced today that it has submitted a supplemental Biologics License Application (BLA) to the U.S. Food...


24 novembre 2017

08:05
Hologic, Inc. announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its Quantratm 2.2 Breast Density Assessment Software, which enables clinicians to provide women with consistent breast...

02:30
Bayer today announced that INHALE, a global Phase III clinical study program investigating Amikacin Inhale in addition to standard of care in intubated and mechanically ventilated patients with Gram-negative pneumonia, did not demonstrate superiority...


23 novembre 2017

11:00
Jennewein Biotechnologie, the world's leading manufacturer of human milk oligosaccharides (HMOs), today announces that it has received a response from the European Commission which includes the decision that, "2'-fucosyllactose powder and liquid...

11:00
Jennewein Biotechnologie, le premier fabricant mondial d'oligosaccharides de lait humain (OLH), annonce aujourd'hui avoir reçu une réponse de la part de la Commission européenne comportant la décision selon laquelle « la poudre et le concentré...

04:00
RÉSERVÉ AUX MÉDIAS MÉDICAUX ET SPÉCIALISÉS   Le guselkumab de Janssen est le premier agent biologique bloquant sélectivement l'interleukine (IL)-23 à être approuvé    Janssen-Cilag International NV a annoncé aujourd'hui que la Commission européenne...

04:00
FOR MEDICAL AND TRADE MEDIA ONLY   Janssen's guselkumab is the first biologic to be approved that selectively blocks interleukin (IL)-23    Janssen-Cilag International NV announced today that the European Commission (EC) has approved TREMFYA®...


22 novembre 2017

15:40
Biliary atresia is the most common cause of liver transplants for children in the United States. Now researchers report in Science Translational Medicine finding a strong biomarker candidate that could be used for earlier diagnosis and lifesaving...

09:30
Eisai Inc. announced today the presentation of eight posters on data, including real-world use of perampanel (marketed as FYCOMPA® CIII). These data will be presented at the American Epilepsy Society (AES) Annual Meeting in Washington, D.C. from...

04:45
Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY study, a Phase II exploratory trial with oral KH176 in the m.3243A>G...

04:45
Data supporting Phase III development of KH176 in mitochondrial disease Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY study,...

04:45
Données soutenant la phase 3 du programme de développement du KH176 pour les maladies mitochondriales  Khondrion, une société de premier plan dans le domaine des produits pharmaceutiques en phase clinique axée sur les petites molécules destinées...

03:00
The website provides patients with helpful information on the company's clinical trials  Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Grouptm, a Swiss-based global biopharmaceutical company, announced today the...

03:00
Le site Internet fournit aux patients des renseignements utiles sur les essais cliniques de la société  Debiopharm International SA (Debiopharm - www.debiopharm.com), membre de Debiopharm Grouptm, société biopharmaceutique mondiale basée en...

03:00
Debiopharm International SA (Debiopharm - www.debiopharm.com), part of Debiopharm Grouptm, a Swiss-based global biopharmaceutical company, announced today the launch of its new clinical trials website patients.debiopharm.com. The website provides...


21 novembre 2017

19:45
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration (FDA) has approved Juluca®, indicated as a complete...

16:05
ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") today announced financial results for the third quarter 2017.   Anthony J. Gringeri, PhD, President and Chief Executive Officer commented: "As a result of the July...

15:09
Elekta (EKTA-B.ST) is introducing its magnetic resonance radiation therapy (MR/RT) technology at the Radiological Society of North America (RSNA) 103rd Annual Meeting in Chicago November 26 to December 1. Elekta's MR-linac is the first system to...

15:06
DelMar Pharmaceuticals, Inc. ("DelMar" or the "Company"), a biopharmaceutical company focused on the development of new cancer therapies, today provided an overview of three scientific posters presented at the 22nd Annual Meeting and Education Day...

09:50
Nevakar LLC, a privately-held specialty pharmaceutical company developing innovative therapies within the injectable and ophthalmic space, today announced that the first subject has been dosed in a Phase 3 clinical trial of NVK-002, the company's...

09:26
AbbVie , a global research and development-based biopharmaceutical company, today announced that the American Society of Hematology (ASH) has accepted data from the Phase 3 MURANO study evaluating venetoclax tablets in combination with rituximab...

09:00
Physicians at Kaiser Permanente in Southern California reduced the odds of prescribing an antibiotic for sinusitis by 22 percent using computer alerts to inform doctors when antibiotics may not be the best course of treatment. The research was...

09:00
A study published in Prostate Cancer and Prostatic Diseases demonstrated that physicians elected to perform fewer biopsies when phi testing was included in their overall, routine, clinical assessment. Phi testing is recommended for men presenting...

08:35
"Herpes is one of those virus that's just amazing at evading our immune system," says Harvey M. Friedman, a professor at the University of Pennsylvania School of Medicine. [1] [2] How does the virus do it?  His team discovered that HSV produces a...

08:00
Audentes Therapeutics, Inc. , a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, today announced the publication of "A Multicenter, Retrospective...

07:00
Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, today announced the publication of preclinical data demonstrating that PR022, the Company's proprietary...

06:30
Ardelyx, Inc. today provided an update on the development of its cardiorenal pipeline. The company's second registration study for tenapanor for the treatment of hyperphosphatemia will begin enrolling shortly, after having received feedback from the...

06:00
Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology is pleased to highlight an expert taskforce review of the incorporation of BEAMing...

06:00
Sysmex Inostics, a subsidiary of Sysmex Corporation, a global leader in blood based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology is pleased to highlight an expert taskforce review of the incorporation of BEAMing...

02:00
Elekta (EKTA-B.ST) announces that 21st Century Oncology, the largest radiation oncology provider in the U.S., will replace several of its existing linear accelerators, as well as treatment planning software and oncology information systems, with...


20 novembre 2017

17:52
A small protein modification can trigger the aggressive migratory and invasive properties of prostate cancer cells, according to new research published on the cover of Oncotarget. The findings give greater insight into how cancers can move from one...

17:36
Quest Diagnostics , the world's leading provider of diagnostic information services, today provided an update on the impact of the Centers for Medicare and Medicaid Services (CMS) publication of finalized 2018 Medicare reimbursement rates for...

15:52
The Leukemia & Lymphoma Society® (LLS) continues to lead the charge to cancer cures through its aggressive research investment; the organization announced today it has committed an additional $46 million to fund the most innovative science at leading...

14:30
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) and Pfizer Global Medical Grants today announced they have awarded funding to nine projects that use clinical care pathways to implement quality improvement (QI)...

10:36
Rethinking Stroke: Groundbreaking New Protocol in the Treatment of Stroke   A groundbreaking new study is helping hospitals and health systems around the world establish protocols that increase the time window of treatment for patients who have...

10:14
Riverside Radiology and Interventional Associates (RRIA), a leading provider of professional radiology services to hospitals and other healthcare providers, today announced the publication of an article co-authored by two RRIA physicians in The New...

09:07
ATCC, an established and trusted source of biological materials in the R&D community, today announced the release of an innovative, in vitro model system for a key mechanism of invasion and metastasis in lung cancer. This model is part of a larger...

09:00
BiondVax Pharmaceuticals Ltd. today announced the signing of the clinical trial agreement (CTA) for a Phase 2 clinical trial with the National Institute of Allergy and Infectious Diseases (NIAID) of the U.S. National Institutes of Health (NIH). The...

09:00
DNAtrix, a leader in the development of oncolytic virus immunotherapies for cancer, announced multiple studies detailing the mechanism and efficacy of DNX-2401 were presented at the 2017 Society for Neuro-Oncology (SNO) Annual Meeting, held in San...

08:32
Aujourd'hui, Takeda et Cognition Kit ont annoncé qu'elles présenteraient les résultats de MDD-5003, une étude pilote visant à examiner les données cognitives et d'évaluation de l'humeur provenant d'une montre Apple Watch chez des patients atteints...

08:05
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023....

08:00
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the first patient has been enrolled in DESTINY-Gastric01, a pivotal phase 2 study in Japan and South Korea evaluating the safety and efficacy of DS-8201, an investigational...

07:00
NanoViricides, Inc. (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), filed its quarterly report for its first quarter of financial year 2018 in a...

07:00
BioLineRx Ltd. , a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that an abstract with partial results from the monotherapy portion of BL-8040's Phase 2a COMBAT study in pancreatic cancer was accepted...

03:00
Biohaven Pharmaceutical Holding Company Ltd. announced today that the Company has received agreement from the U.S. Food and Drug Administration (FDA) on the initial pediatric study plan (iPSP) for orally-dosed rimegepant. Rimegepant is a...

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15